NICE-approved drugs for specialities which fall outside of the services currently provided by the Trust Drug NICE-approved use NICE TA link Abiraterone Abiraterone Adalimumab Adalimumab Adalimumab Adefovir Afatinib Alfa interferon Alirocumab Arsenic trioxide Asfotase alfa Ataluren Atezolizumab Atezolizumab Autologous chondrocyte implantation Avelumab Axicabtagene ciloleucel Axitinib Basiliximab Basiliximab Belimumab Blinatumomab Prostate cancer (castration-resistant) following cytotoxic chemotherapy - Last updated: 27 July 2016 Metastatic hormone-relapsed prostate cancer before chemotherapy is indicated in adults - Last updated: 27 July 2016 Moderate to severe hidradenitis suppurativa (this may only be initiated by Specialist Dermatology Centres). Plaque psoriasis in children and young people Non-infectious uveitis (this may only be initiated by Specialist Ophthalmology Centres). Hepatitis B (chronic) Lung cancer (non small cell, EGFR mutation positive) Primary hypercholesterolaemia or mixed dyslipidaemia Acute promyelocytic leukaemia Paediatric-onset hypophosphatasia Duchenne Muscular Dystrophy Untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable Locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy Symptomatic articular cartilage defects of the knee Metastatic Merkel cell carcinoma Diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies Advanced renal cell carcinoma after failure of prior systemic treatment Active autoantibody-positive systemic lupus erythematosus in adults prescribing is limited to approved specialist centres only. Previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia Note (Aug-17): this therapy may be considered in future. Boceprevir (genotype 1) http://guidance.nice.org.uk/ta259 https://www.nice.org.uk/guidance/ta387 https://www.nice.org.uk/guidance/ta392 https://www.nice.org.uk/guidance/ta455 https://www.nice.org.uk/guidance/ta460 http://guidance.nice.org.uk/ta96 http://guidance.nice.org.uk/ta310 http://guidance.nice.org.uk/ta75 https://www.nice.org.uk/guidance/ta393 https://www.nice.org.uk/guidance/ta526 https://www.nice.org.uk/guidance/hst6 https://www.nice.org.uk/guidance/hst3 https://www.nice.org.uk/guidance/ta492 https://www.nice.org.uk/guidance/ta525 https://www.nice.org.uk/guidance/ta477 https://www.nice.org.uk/guidance/ta517 https://www.nice.org.uk/guidance/ta559 https://www.nice.org.uk/guidance/ta333 https://www.nice.org.uk/guidance/ta397 https://www.nice.org.uk/guidance/ta450 http://guidance.nice.org.uk/ta253
Burosumab Cabazitaxel Cabozantinib Cabozantinib Cabozantinib Capecitabine Capecitabine Capecitabine Carmustine and panitumumab Cladribine Cobimetinib Collagenase clostridium histolyticum Crizotinib Crizotinib Dabrafenib with trametinib Dabrafenib Daclatasvir Daclizumab Daclizumab Degarelix Dinutuximab beta Docetaxel Docetaxel Doxorubicin Eculizumab X-linked hypophosphataemia in children and young people Hormone-relapsed metastatic prostate cancer treated with docetaxel Previously treated advanced renal cell carcinoma Medullary thyroid cancer Untreated advanced renal cell carcinoma Colorectal cancer Colon cancer (adjuvant) Gastric cancer (advanced) Glioma (newly diagnosed and high-grade) Previously untreated metastatic colorectal cancer Head and neck cancer Colorectal cancer (first-line treatment) Recurrent or metastatic squamous cell cancer of the head and neck Previously untreated metastatic colorectal cancer Relapsing remitting multiple sclerosis (This may be possible to prescribe under shared care with an NHS England approved Tertiary Centre for MS) In combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma Dupuytren's contracture Untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer Adjuvant treatment of resected BRAF V600 mutationpositive melanoma Unresectable or metastatic BRAF V600 mutation positive melanoma Advanced hormone-dependent prostate cancer Neuroblastoma Prostate cancer (hormone-refractory) Breast cancer (early) Atypical haemolytic uraemic syndrome https://www.nice.org.uk/guidance/hst8 https://www.nice.org.uk/guidance/ta391 https://www.nice.org.uk/guidance/ta463 https://www.nice.org.uk/guidance/ta516 https://www.nice.org.uk/guidance/ta542 http://guidance.nice.org.uk/ta61 http://guidance.nice.org.uk/ta100 http://guidance.nice.org.uk/ta191 http://guidance.nice.org.uk/ta121 https://www.nice.org.uk/guidance/ta439 http://guidance.nice.org.uk/ta145 http://guidance.nice.org.uk/ta176 https://www.nice.org.uk/guidance/ta473 https://www.nice.org.uk/guidance/ta439 https://www.nice.org.uk/guidance/ta493 https://www.nice.org.uk/guidance/ta414 https://www.nice.org.uk/guidance/ta459 https://www.nice.org.uk/guidance/ta406 https://www.nice.org.uk/guidance/ta422 https://www.nice.org.uk/guidance/ta544 https://www.nice.org.uk/guidance/ta321 http://www.nice.org.uk/guidance/ta364 https://www.nice.org.uk/guidance/ta404 https://www.nice.org.uk/guidance/ta538 http://guidance.nice.org.uk/ta101 http://guidance.nice.org.uk/ta109 https://www.nice.org.uk/guidance/hst1
Elbasvir grazoprevir Eliglustat Encorafenib with binimetinib Entecavir Enzalutamide Enzalutamide Eribulin Erlotinib Erlotinib Erlotinib Etelcalcetide Everolimus Everolimus Everolimus Evolocumab Gefitinib Gefitinib Gemcitabine Gemcitabine Gemcitabine Glecaprevir pibrentasvir Holoclar Imatinib Imatinib Imatinib Immunosuppressive therapy Immunosuppressive therapy Inotuzumab ozogamicin Intrabeam radiotherapy system Ipilimumab Type 1 Gaucher disease Unresectable or metastatic BRAF V600 mutationpositive melanoma Hepatitis B Metastatic hormone relapsed prostate cancer previously treated with a docetaxel containing regimen Metastatic hormone-relapsed prostate cancer before chemotherapy is indicated Locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens Lung cancer (non-small cell) Lung cancer (non-small cell, EGFR-TK mutation positive, first-line treatment) Non-small-cell lung cancer that has progressed after prior chemotherapy Secondary hyperparathyroidism Advanced renal cell carcinoma after previous treatment Advanced breast cancer after endocrine therapy Unresectable or metastatic neuroendocrine tumours in people with progressive disease Primary hypercholesterolaemia or mixed dyslipidaemia. (Restricted to named specialist centres only) Lung cancer (non-small cell, first-line treatment) Non-small-cell lung cancer that has progressed after prior chemotherapy Pancreatic cancer Breast cancer Limbal stem cell deficiency after eye burns Gastrointestinal stromal tumours Gastrointestinal stromal tumours (unresectable/metastatic) Adjuvant treatment of gastrointestinal stromal tumours Kidney transplant in adults kidney transplant in children and young people Relapsed or refractory B-cell acute lymphoblastic leukaemia Adjuvant treatment of early breast cancer Previously treated advanced (unresectable or metastatic) melanoma https://www.nice.org.uk/guidance/ta413 https://www.nice.org.uk/guidance/hst5 https://www.nice.org.uk/guidance/ta562 http://guidance.nice.org.uk/ta153 https://www.nice.org.uk/guidance/ta316 https://www.nice.org.uk/guidance/ta377 https://www.nice.org.uk/guidance/ta423 http://guidance.nice.org.uk/ta162 http://guidance.nice.org.uk/ta258 http://www.nice.org.uk/guidance/ta374 https://www.nice.org.uk/guidance/ta448 https://www.nice.org.uk/guidance/ta432 https://www.nice.org.uk/guidance/ta421 https://www.nice.org.uk/guidance/ta449 https://www.nice.org.uk/guidance/ta394 http://guidance.nice.org.uk/ta192 http://www.nice.org.uk/guidance/ta374 http://guidance.nice.org.uk/ta25 http://guidance.nice.org.uk/ta116 https://www.nice.org.uk/guidance/ta499 https://www.nice.org.uk/guidance/ta467 http://guidance.nice.org.uk/ta86 http://guidance.nice.org.uk/ta209 https://www.nice.org.uk/guidance/ta326 https://www.nice.org.uk/guidance/ta481 https://www.nice.org.uk/guidance/ta482 https://www.nice.org.uk/guidance/ta541 https://www.nice.org.uk/guidance/ta501 http://guidance.nice.org.uk/ta268
Ipilimumab Lapatinib Ledipasvir sofosbuvir Lenvatinib with everolimus Lenvatinib and sorafenib Lenvatinib Liposomal cytarabine daunorubicin Lutetium (177Lu) oxodotreotide Mepolizumab Midostaurin Mifamurtide Migalastat Nalmefene Necitumumab Nintedanib Niraparib Olaparib Olaratumab in combination with doxorubicin Ombitasvir paritaprevir ritonavir Previously untreated advanced (unresectable or metastatic) melanoma Breast cancer (metastatic hormone receptor) with aromatase inhibitor Previously treated advanced renal cell carcinoma Differentiated thyroid cancer after radioactive iodine Untreated advanced hepatocellular carcinoma Untreated acute myeloid leukaemia Patients will be treated at RSCH as inpatient. Unresectable or metastatic neuroendocrine tumours Severe refractory eosinophilic asthma. Please note: pending NHS England small services review of ASPH Q4 2016/17 this may change. Untreated acute myeloid leukaemia Osteosarcoma Fabry disease Reducing alcohol consumption in people with alcohol dependence Untreated advanced or metastatic squamous non-smallcell lung cancer Locally advanced, metastatic or locally recurrent nonsmall-cell lung cancer Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer Advanced (unresectable or metastatic) melanoma Advanced (unresectable or metastatic) melanoma in adults, in combination with ipilimumab Previously treated advanced renal cell carcinoma Squamous cell carcinoma of the head and neck after platinum-based chemotherapy Completely resected melanoma with lymph node involvement or metastatic disease Maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy Advanced soft tissue sarcoma With or without dasabuvir for treating chronic hepatitis C https://www.nice.org.uk/guidance/ta319 http://guidance.nice.org.uk/ta257 http://www.nice.org.uk/guidance/ta363 https://www.nice.org.uk/guidance/ta498 https://www.nice.org.uk/guidance/ta535 https://www.nice.org.uk/guidance/ta551 https://www.nice.org.uk/guidance/ta552 https://www.nice.org.uk/guidance/ta539 https://www.nice.org.uk/guidance/ta431 https://www.nice.org.uk/guidance/ta523 http://guidance.nice.org.uk/ta235 https://www.nice.org.uk/guidance/hst4 https://www.nice.org.uk/guidance/ta325 https://www.nice.org.uk/guidance/ta411 http://www.nice.org.uk/guidance/ta347 https://www.nice.org.uk/guidance/ta528 https://www.nice.org.uk/guidance/ta384 https://www.nice.org.uk/guidance/ta400 https://www.nice.org.uk/guidance/ta417 https://www.nice.org.uk/guidance/ta490 https://www.nice.org.uk/guidance/ta558 https://www.nice.org.uk/guidance/ta381 https://www.nice.org.uk/guidance/ta465 http://www.nice.org.uk/guidance/ta365
Osimertinib Oxaliplatin Paclitaxel Paclitaxel Paclitaxel Pazopanib Pegaspargase Pegylated interferons Pegylated interferon alfa 2a Peginterferon alfa Peginterferon alfa Peginterferon alfa with Pemetrexed Pertuzumab Pharmalgen Radium-223 dichloride Radium-223 dichloride Ramucirumab Regorafenib Regorafenib Reslizumab Riluzole Locally advanced or metastatic EGFR T790M mutationpositive non-small-cell lung cancer Colon cancer (adjuvant) Ovarian cancer review As albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer Renal cell carcinoma (first-line metastatic) Acute lymphoblastic leukaemia Hepatitis B (chronic) Advanced Melanoma Advanced melanoma not previously treated with ipilimumab Locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy Untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable Resected melanoma with high risk of recurrence Mesothelioma neoadjuvant treatment of HER2-positive breast cancer Venom anaphylaxis immunotherapy Pharmalgen Hormone-relapsed prostate cancer with bone metastases Hormone-relapsed prostate cancer with bone metastases Previously treated locally advanced or metastatic nonsmall-cell lung cancer Previously treated unresectable or metastatic gastrointestinal stromal tumours Previously treated advanced hepatocellular carcinoma Severe eosinophilic asthma *Note: This is subject to change if ASPH is approved as a specialist centre for Respiratory/Asthma.* Motor neurone disease https://www.nice.org.uk/guidance/ta416 http://guidance.nice.org.uk/ta100 http://guidance.nice.org.uk/ta55 https://www.nice.org.uk/guidance/ta476 http://guidance.nice.org.uk/ta215 https://www.nice.org.uk/guidance/ta408 http://guidance.nice.org.uk/ta75 http://guidance.nice.org.uk/ta96 http://guidance.nice.org.uk/ta106 http://guidance.nice.org.uk/ta200 http://guidance.nice.org.uk/ta300 http://www.nice.org.uk/guidance/ta357 http://www.nice.org.uk/guidance/ta366 https://www.nice.org.uk/guidance/ta519 https://www.nice.org.uk/guidance/ta522 https://www.nice.org.uk/guidance/ta553 http://guidance.nice.org.uk/135 https://www.nice.org.uk/guidance/ta424 http://guidance.nice.org.uk/ta246 https://www.nice.org.uk/guidance/ta376 https://www.nice.org.uk/guidance/ta412 https://www.nice.org.uk/guidance/ta403 https://www.nice.org.uk/guidance/ta488 https://www.nice.org.uk/guidance/ta555 https://www.nice.org.uk/guidance/ta479 http://guidance.nice.org.uk/ta75 http://guidance.nice.org.uk/ta106 http://guidance.nice.org.uk/ta200 http://guidance.nice.org.uk/ta20
Simepravir Sirolimus Sirolimus Sofosbuvir Sofosbuvir velpatasvir Sofosbuvir velpatasvir voxilaprevir Sorafenib Sunitinib Sunitinib Sunitinib Tacrolimus Tacrolimus Talimogene laherparepvec Tegafur uracil In combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C Chronic Chronic Chronic Advanced hepatocellular carcinoma Renal cell carcinoma Gastrointestinal stromal tumours Unresectable or metastatic neuroendocrine tumours in people with progressive disease Unresectable metastatic melanoma Colorectal cancer Telaprevir (genotype 1) Temozolamide Temozolamide Tenofovir Tisagenlecleucel Tivozanib Tocilizumab Topotecan Topotecan Topotecan Trabectedin Trabectedin Trametinib Trifluridine Vemurafenib Vismodegib Vortioxetine Brain cancer Glioma (newly diagnosed and high-grade) Hepatitis B Relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years Advanced renal cell carcinoma Giant cell arteritis (Tertiary Centres Only) Cervical cancer (recurrent) Lung cancer (small cell) Soft tissue sarcoma In combination with dabrafenib for treating unresectable or metastatic melanoma Previously treated metastatic colorectal cancer Melanoma (BRAF V600 mutation positive, unresectable metastatic) Basal cell carcinoma Major depressive episodes https://www.nice.org.uk/guidance/ta331 https://www.nice.org.uk/guidance/ta330 https://www.nice.org.uk/guidance/ta430 https://www.nice.org.uk/guidance/ta507 https://www.nice.org.uk/guidance/ta474 http://guidance.nice.org.uk/ta169 http://guidance.nice.org.uk/ta179 https://www.nice.org.uk/guidance/ta449 https://www.nice.org.uk/guidance/ta410 http://guidance.nice.org.uk/ta61 http://guidance.nice.org.uk/ta252 https://www.nice.org.uk/guidance/ta23 http://guidance.nice.org.uk/ta121 http://guidance.nice.org.uk/ta173 https://www.nice.org.uk/guidance/ta554 https://www.nice.org.uk/guidance/ta512 https://www.nice.org.uk/guidance/ta518 http://guidance.nice.org.uk/ta183 http://guidance.nice.org.uk/ta184 http://guidance.nice.org.uk/ta185 https://www.nice.org.uk/guidance/ta396 https://www.nice.org.uk/guidance/ta405 http://guidance.nice.org.uk/ta269 https://www.nice.org.uk/guidance/ta489 http://www.nice.org.uk/guidance/ta367